This is a table of type trigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
trigram | frequency |
---|---|
background case studies | 481 |
study design method | 387 |
the use of | 318 |
as well as | 314 |
or case report | 241 |
purpose or case | 241 |
the development of | 217 |
the united states | 216 |
the number of | 199 |
in order to | 194 |
food and drug | 187 |
and drug administration | 182 |
one of the | 168 |
in patients with | 167 |
the treatment of | 159 |
in addition to | 151 |
the risk of | 149 |
in the united | 149 |
due to the | 140 |
study design methods | 138 |
the presence of | 132 |
a total of | 128 |
based on the | 118 |
to determine the | 105 |
the need for | 98 |
red blood cells | 97 |
the purpose of | 96 |
there is a | 93 |
such as the | 90 |
for the treatment | 89 |
a variety of | 85 |
the detection of | 84 |
guidance for industry | 84 |
of this study | 84 |
red blood cell | 81 |
the implementation of | 80 |
a number of | 79 |
the blood bank | 79 |
the most common | 78 |
by the fda | 75 |
in the treatment | 74 |
some of the | 73 |
be used to | 72 |
purpose of this | 71 |
was used to | 71 |
in this study | 70 |
the majority of | 67 |
according to the | 67 |
the ability to | 66 |
to evaluate the | 66 |
for the detection | 66 |
there was no | 65 |
of patients with | 65 |
need to be | 65 |
study was to | 64 |
the evaluation of | 64 |
compared to the | 64 |
it is important | 64 |
this study was | 64 |
may not be | 63 |
part of the | 63 |
as a result | 63 |
use of the | 63 |
review of the | 62 |
role in the | 62 |
for use in | 62 |
evaluation of the | 62 |
at our institution | 61 |
use of a | 61 |
used in the | 61 |
can be used | 61 |
it has been | 61 |
at the time | 60 |
implementation of the | 59 |
the time of | 59 |
used to treat | 58 |
the role of | 58 |
in the us | 57 |
related to the | 57 |
is important to | 57 |
in the pediatric | 57 |
to reduce the | 56 |
the us fda | 56 |
were used to | 55 |
the impact of | 55 |
acute respiratory syndrome | 54 |
severe acute respiratory | 54 |
to assess the | 53 |
of the disease | 52 |
the effect of | 52 |
of the product | 52 |
the safety of | 52 |
and safety of | 52 |
the case of | 51 |
addition to the | 51 |
safety and efficacy | 51 |
the lack of | 51 |
to ensure that | 51 |
associated with the | 51 |
the identification of | 51 |
as part of | 51 |
the quality of | 51 |
the potential to | 51 |
the efficacy of | 50 |
the food and | 50 |
the steering committee | 50 |
of the most | 50 |
the diagnosis of | 49 |
in response to | 49 |
has not been | 49 |
the objective of | 49 |
the importance of | 49 |
have been reported | 48 |
fda approved drugs | 48 |
depending on the | 47 |
the level of | 47 |
that can be | 47 |
in the case | 47 |
can lead to | 46 |
center background case | 46 |
a history of | 46 |
development of a | 46 |
found to be | 46 |
the harmonization of | 45 |
included in the | 45 |
the incidence of | 45 |
the absence of | 45 |
the aim of | 45 |
there is no | 45 |
the university of | 45 |
have been developed | 45 |
most of the | 44 |
over the past | 44 |
years of age | 44 |
fda labels for | 44 |
well as the | 44 |
the establishment of | 43 |
a review of | 43 |
the production of | 43 |
there was a | 43 |
it is a | 43 |
each of the | 43 |
because of the | 42 |
involved in the | 42 |
in the development | 42 |
that have been | 42 |
hepatitis c virus | 42 |
been shown to | 42 |
prior to the | 42 |
for patients with | 42 |
a and b | 41 |
the potential for | 41 |
the creation of | 41 |
the need to | 41 |
of a new | 41 |
the fact that | 41 |
has also been | 41 |
efficacy and safety | 41 |
was performed using | 40 |
be able to | 40 |
is one of | 40 |
in of patients | 40 |
before and after | 40 |
in combination with | 39 |
the results of | 39 |
have also been | 39 |
the human genome | 39 |
world health organization | 39 |
the safety and | 39 |
resulted in a | 39 |
of the virus | 39 |
of the eu | 39 |
objective of this | 39 |
the end of | 39 |
understanding of the | 39 |
is responsible for | 39 |
an average of | 38 |
approved by the | 38 |
in which the | 38 |
mechanism of action | 38 |
at least one | 38 |
is associated with | 38 |
has been reported | 38 |
of the patients | 38 |
the patient was | 38 |
used for the | 38 |
in the eu | 38 |
associated with a | 38 |
in the setting | 37 |
wide range of | 37 |
the development and | 37 |
was found to | 37 |
to determine if | 37 |
harmonization of pharmaceutical | 37 |
head and neck | 37 |
a patient with | 37 |
some of these | 36 |
is the most | 36 |
the setting of | 36 |
disinfection and sterilization | 36 |
the management of | 36 |
the effectiveness of | 36 |
there were no | 36 |
of the first | 35 |
as compared to | 35 |
the goal of | 35 |
for treatment of | 35 |
of blood products | 35 |
ich steering committee | 35 |
a wide range | 35 |
of the ich | 35 |
and efficacy of | 35 |
was associated with | 35 |
exchange of information | 35 |
was performed by | 34 |
of the drug | 34 |
the frequency of | 34 |
the amount of | 34 |
the possibility of | 34 |
is based on | 34 |
for detection of | 34 |
weak d type | 34 |
were reported in | 34 |
the ich steering | 34 |
respiratory syndrome coronavirus | 34 |
of the new | 34 |
the pediatric population | 34 |
by the food | 34 |
be used for | 34 |
it is not | 34 |
based on a | 34 |
hematopoietic stem cell | 34 |
in the literature | 34 |
has indicated that | 34 |
in the blood | 33 |
united states food | 33 |
for disease control | 33 |
is used to | 33 |
development of the | 33 |
in the region | 33 |
increase in the | 33 |
the prevalence of | 33 |
of health and | 32 |
it is also | 32 |
the availability of | 32 |
retrospective review of | 32 |
the transfusion service | 32 |
magnetic resonance imaging | 32 |
to ensure the | 32 |
in the past | 32 |
states food and | 32 |
to improve the | 32 |
of the european | 32 |
study is to | 32 |
in terms of | 32 |
human immunodeficiency virus | 32 |
influenza a h | 32 |
the fda has | 32 |
in the future | 32 |
sickle cell disease | 32 |
a result of | 31 |
in vitro and | 31 |
this study is | 31 |
and in the | 31 |
in a patient | 31 |
the ability of | 31 |
control and prevention | 31 |
the basis of | 31 |
the context of | 31 |
and the us | 31 |
of the pediatric | 31 |
the performance of | 31 |
to be a | 31 |
to support the | 31 |
should not be | 31 |
this is a | 31 |
an increase in | 31 |
in the presence | 31 |
centers for disease | 31 |
for evaluation of | 31 |
congenital heart disease | 31 |
there are no | 31 |
health and human | 30 |
of the study | 30 |
due to its | 30 |
of clinical trials | 30 |
disease control and | 30 |
research and development | 30 |
the past years | 30 |
in pediatric patients | 30 |
used as a | 30 |
of the blood | 29 |
use of antibiotics | 29 |
end of the | 29 |
analysis of the | 29 |
an important role | 29 |
of blood components | 29 |
classified by the | 29 |
important role in | 29 |
for the development | 29 |
american red cross | 29 |
at the same | 29 |
was performed to | 29 |
european medicines agency | 29 |
in accordance with | 29 |
the discovery of | 29 |
the member states | 29 |
all of the | 29 |
has been shown | 29 |
to facilitate the | 29 |
and human services | 29 |
a medical device | 29 |
of pharmaceutical regulations | 29 |
increased risk of | 29 |
to provide a | 29 |
to have a | 29 |
due to a | 29 |
with respect to | 29 |
morbidity and mortality | 29 |
the european medicines | 29 |
of a medical | 29 |
response to the | 29 |
department of health | 28 |
to be the | 28 |
use in the | 28 |
in the educational | 28 |
for up to | 28 |
in the context | 28 |
in children with | 28 |
discuss or describe | 28 |
was determined by | 28 |
for the evaluation | 28 |
the public health | 28 |
to the fda | 28 |
been reported in | 28 |
the world health | 28 |
on the other | 28 |
and can be | 28 |
sensitivity and specificity | 28 |
public health emergency | 28 |
imaging findings of | 28 |
will discuss or | 28 |
the effects of | 28 |
a retrospective review | 28 |
medical device or | 28 |
a case of | 28 |
shown to be | 28 |
a series of | 28 |
a range of | 28 |
safe and effective | 28 |
polymerase chain reaction | 27 |
members of the | 27 |
the course of | 27 |
has the potential | 27 |
vitro and in | 27 |
has been used | 27 |
reduce the risk | 27 |
pharmaceutical that is | 27 |
investigational for intended | 27 |
american college of | 27 |
a use of | 27 |
in the usa | 27 |
of the test | 27 |
the same time | 27 |
that is classified | 27 |
aim of this | 27 |
emergency use authorization | 27 |
should be considered | 27 |
of these patients | 27 |
in the first | 27 |
the educational content | 27 |
is classified by | 27 |
for intended use | 27 |
of the human | 27 |
was performed on | 27 |
have shown that | 27 |
and implementation of | 27 |
the percentage of | 27 |
device or pharmaceutical | 27 |
or pharmaceutical that | 27 |
in the absence | 27 |
of the patient | 27 |
as investigational for | 27 |
blood and blood | 26 |
were observed in | 26 |
the introduction of | 26 |
in the s | 26 |
to note that | 26 |
could not be | 26 |
up to days | 26 |
the age of | 26 |
to identify the | 26 |
likely to be | 26 |
the department of | 25 |
with the use | 25 |
the rate of | 25 |
of the donor | 25 |
found in the | 25 |
of fda approved | 25 |
for human use | 25 |
on the basis | 25 |
obtained from the | 25 |
the other hand | 25 |
the formation of | 25 |
to determine whether | 25 |
have not been | 25 |
dependent rna polymerase | 25 |
with regard to | 25 |
and development of | 25 |
may also be | 25 |
to investigate the | 25 |
when compared to | 25 |
will be presented | 25 |
a transfusion vol | 25 |
significant difference in | 25 |
this is the | 25 |
treatment of covid | 25 |
electronic medical record | 25 |
kcal mol and | 25 |
should also be | 25 |
were found to | 25 |
be associated with | 25 |
have been used | 25 |
in the same | 25 |
none of the | 25 |
do not have | 25 |
that may be | 24 |
knowledge of the | 24 |
the assessment of | 24 |
no significant differences | 24 |
middle east respiratory | 24 |
to develop a | 24 |
was observed in | 24 |
in the study | 24 |
to the development | 24 |
differences in the | 24 |
a reduction in | 24 |
can also be | 24 |
of a single | 24 |
information on the | 24 |
testing was performed | 24 |
and management of | 24 |
east respiratory syndrome | 24 |
any of the | 24 |
of the pharmaceutical | 24 |
docking score of | 24 |
in both the | 24 |
during the first | 24 |
in the evaluation | 24 |
of the clinical | 24 |
west nile virus | 24 |
section of the | 24 |
in recent years | 24 |
patients with a | 24 |
are based on | 24 |
type and screen | 24 |
clinical trials in | 24 |
in the number | 24 |
were performed on | 24 |
antibiotic use in | 24 |
hepatitis b virus | 24 |
has led to | 23 |
the spectrum of | 23 |
total number of | 23 |
school of medicine | 23 |
in the pharmaceutical | 23 |
the product is | 23 |
medical center background | 23 |
added to the | 23 |
of public health | 23 |
and use of | 23 |
observed in the | 23 |
will also be | 23 |
of blood donors | 23 |
reported in the | 23 |
the animal rule | 23 |
of red blood | 23 |
in a large | 23 |
patient blood management | 23 |
assessment of the | 23 |
studies have shown | 23 |
in the clinical | 23 |
of medicinal products | 23 |
of the current | 23 |
a combination of | 23 |
is critical to | 23 |
in this case | 22 |
is necessary to | 22 |
in clinical trials | 22 |
exhibit is to | 22 |
standard of care | 22 |
and in vivo | 22 |
half of the | 22 |
and of the | 22 |
more likely to | 22 |
to demonstrate the | 22 |
and public health | 22 |
the fda and | 22 |
the field of | 22 |
is needed to | 22 |
the ema and | 22 |
in some cases | 22 |
the adoption of | 22 |
a systematic review | 22 |
responsible for the | 22 |
are needed to | 22 |
was to evaluate | 22 |
assessment report of | 22 |
was performed in | 22 |
after the first | 22 |
assisted laser desorption | 22 |
over the years | 22 |
the exchange of | 22 |
to create a | 22 |
the type of | 22 |
that there is | 21 |
and for the | 21 |
will be discussed | 21 |
it is the | 21 |
difference between the | 21 |
important to note | 21 |
is the first | 21 |
a lack of | 21 |
was defined as | 21 |
found to have | 21 |
for the first | 21 |
with a history | 21 |
in a single | 21 |
there has been | 21 |
to review the | 21 |
intensive care unit | 21 |
needs to be | 21 |
implementation of a | 21 |
led to a | 21 |
us food and | 21 |
the ich regions | 21 |
performance of the | 21 |
in relation to | 21 |
impact on the | 21 |
a docking score | 21 |
in the world | 21 |
member of the | 21 |
caused by the | 21 |
reported to be | 21 |
the expression of | 21 |
used to determine | 21 |
the levels of | 21 |
development of new | 21 |
been reported to | 21 |
the blood center | 21 |
led to the | 21 |
safety of the | 21 |
was used for | 21 |
weak d types | 21 |
the scope of | 21 |
ligand efficiency of | 21 |
the most important | 21 |
analysis was performed | 20 |
respiratory syncytial virus | 20 |
the extent of | 20 |
in this regard | 20 |
and harmonization of | 20 |
to address the | 20 |
the european union | 20 |
at the university | 20 |
was reported in | 20 |
in the field | 20 |
and treatment of | 20 |
laser desorption ionization | 20 |
be used as | 20 |
herpes simplex virus | 20 |
the fda to | 20 |
to the blood | 20 |
in a study | 20 |
massive transfusion protocol | 20 |
has been a | 20 |
patients who received | 20 |
central nervous system | 20 |
in the diagnosis | 20 |
the process of | 20 |
a group of | 20 |
the area of | 20 |
in cases of | 20 |
the addition of | 20 |
a h n | 20 |
the mechanism of | 20 |
with or without | 20 |
the most commonly | 20 |
many of these | 20 |
the us and | 20 |
for the diagnosis | 20 |
as a potential | 20 |
the study period | 20 |
interstitial lung disease | 20 |
in the early | 20 |
one or more | 20 |
in conjunction with | 20 |
more than one | 20 |
along with the | 20 |
a clinical trial | 19 |
which may be | 19 |
by flow cytometry | 19 |
of the assay | 19 |
in the ema | 19 |
patients with severe | 19 |
cd t cells | 19 |
at risk of | 19 |
did not have | 19 |
for identification of | 19 |
the fda in | 19 |
there is an | 19 |
is an important | 19 |
the value of | 19 |
of whole blood | 19 |
the prevention of | 19 |
in the u | 19 |
of ebola virus | 19 |
each of these | 19 |
were able to | 19 |
the american college | 19 |
to detect the | 19 |
at risk for | 19 |
patients treated with | 19 |
one of these | 19 |
many of the | 19 |
supported by the | 19 |
high levels of | 19 |
of antibiotics in | 19 |
provided by the | 19 |
indicated that he | 19 |
between the two | 19 |
the application of | 19 |
determined to be | 19 |
been used to | 19 |
was seen in | 19 |
the difference between | 19 |
identified in the | 19 |
should be used | 19 |
to compare the | 19 |
it is possible | 19 |
in contrast to | 19 |
therapeutic plasma exchange | 19 |
part of a | 19 |
at the end | 19 |
continue to be | 19 |
of which were | 19 |
blood center background | 19 |
of the viral | 19 |
the duration of | 19 |
change in the | 19 |
which has been | 19 |
the study was | 19 |
blood and marrow | 19 |
could be used | 19 |
better understanding of | 19 |
structure of the | 19 |
within hours of | 19 |
present in the | 19 |
to be used | 19 |
in the event | 19 |
there have been | 19 |
a list of | 19 |
an overview of | 19 |
it may be | 19 |
were obtained from | 18 |
the sensitivity of | 18 |
are associated with | 18 |
ema assessment report | 18 |
the nature of | 18 |
the basis for | 18 |
code of federal | 18 |
may lead to | 18 |
and identification of | 18 |
the donor is | 18 |
flight mass spectrometry | 18 |
stem cell transplantation | 18 |
the activity of | 18 |
effectiveness of the | 18 |
be due to | 18 |
continues to be | 18 |
regions of the | 18 |
case of a | 18 |
it should be | 18 |
impact of the | 18 |
medicinal products for | 18 |
peripheral blood stem | 18 |
been associated with | 18 |
significant differences in | 18 |
the blood supply | 18 |
the increase in | 18 |
be used in | 18 |
resulted in the | 18 |
to establish the | 18 |
an effort to | 18 |
we present a | 18 |
of the system | 18 |
of the american | 18 |
up to of | 18 |
with an average | 18 |
is used in | 18 |
the pharmaceutical industry | 18 |
at this time | 18 |
pediatric patients with | 18 |
in most cases | 18 |
in the post | 18 |
a set of | 18 |
pre and post | 18 |
were included in | 18 |
whether or not | 18 |
large number of | 18 |
ebola virus disease | 18 |
in all cases | 18 |
of the federal | 18 |
fd c act | 18 |
disease of the | 18 |
the benefits of | 18 |
of federal regulations | 18 |
risk factors for | 18 |
is known to | 18 |
the risks of | 18 |
the ema assessment | 18 |
the severity of | 18 |
of more than | 18 |
is a rare | 18 |
stored for days | 18 |
have the potential | 18 |
a summary of | 18 |
not associated with | 17 |
a diagnosis of | 17 |
difference in the | 17 |
was able to | 17 |
diseases such as | 17 |
use in food | 17 |
it is critical | 17 |
which is a | 17 |
the centers for | 17 |
all of these | 17 |
the cost of | 17 |
presence of a | 17 |
and lack of | 17 |
regional blood center | 17 |
canadian blood services | 17 |
lead to a | 17 |
the patient and | 17 |
appear to be | 17 |
of transmission of | 17 |
of the major | 17 |
and should be | 17 |
was to determine | 17 |
and the fda | 17 |
diagnosis and treatment | 17 |
will continue to | 17 |
also known as | 17 |
this educational exhibit | 17 |
the accuracy of | 17 |
treatment of patients | 17 |
number of units | 17 |
is required to | 17 |
the electronic medical | 17 |
broad range of | 17 |
in the last | 17 |
with a docking | 17 |
compared with the | 17 |
the review of | 17 |
revealed that the | 17 |
a role in | 17 |
used to assess | 17 |
in animal feed | 17 |
the american society | 17 |
are required to | 17 |
evaluation of a | 17 |
a public health | 17 |
have been shown | 17 |
clinical trials for | 17 |
considered to be | 17 |
a decrease in | 17 |
in comparison to | 17 |
is a major | 17 |
the emergence of | 17 |
were associated with | 17 |
were tested for | 17 |
that do not | 17 |
in the area | 17 |
investigational new drug | 17 |
the total number | 17 |
of the time | 17 |
quality and safety | 17 |
no significant difference | 17 |
and cosmetic act | 17 |
months of age | 17 |
of red cell | 17 |
a large number | 17 |
suggest that the | 17 |
the last years | 17 |
hospital background case | 17 |
limit of detection | 17 |
quality of the | 17 |
the vitek ms | 17 |
that of the | 16 |
fda and the | 16 |
at the national | 16 |
size of the | 16 |
of these cases | 16 |
signs and symptoms | 16 |
mol and ligand | 16 |
to describe the | 16 |
a spectrum of | 16 |
the active site | 16 |
the degree of | 16 |
approved for use | 16 |
the ich process | 16 |
fresh frozen plasma | 16 |
approximately of the | 16 |
by the ema | 16 |
the immune system | 16 |
over the last | 16 |
outside of the | 16 |
the fd c | 16 |
submitted to the | 16 |
and ligand efficiency | 16 |
the united kingdom | 16 |
to our knowledge | 16 |
of influenza a | 16 |
donors in the | 16 |
in vitro quality | 16 |
to study the | 16 |
around the world | 16 |
and it is | 16 |
by the manufacturer | 16 |
risks associated with | 16 |
has resulted in | 16 |
establishment of the | 16 |
high risk of | 16 |
study of the | 16 |
for use of | 16 |
in public health | 16 |
the face of | 16 |
of the sars | 16 |
in transfusion medicine | 16 |
will be used | 16 |
american society for | 16 |
has been developed | 16 |
critically ill patients | 16 |
known to be | 16 |
from the fda | 16 |
to be an | 16 |
in the following | 16 |
appearance of the | 16 |
data on the | 16 |
ct and mri | 16 |
was the first | 16 |
as an important | 16 |
of pediatric radiology | 16 |
was designed to | 16 |
to the current | 16 |
of the world | 16 |
of medically important | 16 |
out of the | 16 |
information about the | 16 |
a broad range | 16 |
a member of | 16 |
in both groups | 16 |
implementation of this | 16 |
virus infection in | 16 |
good manufacturing practice | 16 |
based on this | 16 |
for the prevention | 16 |
establishment of a | 16 |
majority of the | 16 |
well as to | 16 |
is a common | 16 |
number of patients | 16 |
the regulation of | 16 |
the size of | 16 |
a change in | 16 |
were evaluated for | 16 |
were found in | 16 |
may be a | 16 |
the phs act | 16 |
seasonal influenza a | 15 |
of action of | 15 |
in this area | 15 |
the image gently | 15 |
with a high | 15 |
are involved in | 15 |
of the potential | 15 |
academic medical center | 15 |
of transfusion medicine | 15 |
the european commission | 15 |
at high risk | 15 |
a dose of | 15 |
for the use | 15 |
of patients who | 15 |
the result of | 15 |
with and without | 15 |
was created to | 15 |
to develop and | 15 |
of the vaccine | 15 |
public health and | 15 |
we report a | 15 |
hemolytic transfusion reactions | 15 |
ema and the | 15 |
small number of | 15 |
from the same | 15 |
by the american | 15 |
the vast majority | 15 |
in the production | 15 |
national medical center | 15 |
and the ema | 15 |
goal of this | 15 |
the feasibility of | 15 |
in health care | 15 |
patients with covid | 15 |
that he will | 15 |
of the fetus | 15 |
to provide an | 15 |
samples were tested | 15 |
the existence of | 15 |
that has been | 15 |
of the fda | 15 |
associated with increased | 15 |
used to evaluate | 15 |
a wide variety | 15 |
whole blood and | 15 |
the efficacy and | 15 |
that are not | 15 |
creation of the | 15 |
to meet the | 15 |
it is an | 15 |
to be performed | 15 |
a year old | 15 |
comparison of the | 15 |
and control of | 15 |
may be used | 15 |
time of flight | 15 |
of the national | 15 |
the diagnosis and | 15 |
assay for the | 15 |
cancer drug manual | 15 |
chronic hepatitis c | 15 |
what is the | 15 |
donors should be | 15 |
the success of | 15 |
used as an | 15 |
are likely to | 15 |
health care professionals | 15 |
wide variety of | 15 |
is essential to | 15 |
were divided into | 15 |
the federal food | 15 |
consistent with the | 15 |
has been the | 15 |
is not a | 15 |
at room temperature | 15 |
determine if the | 15 |
found that the | 15 |
nature of the | 15 |
are used to | 15 |
in a timely | 15 |
in the face | 15 |
and may be | 15 |
for at least | 15 |
safety and effectiveness | 15 |
the results were | 15 |
the centralized procedure | 15 |
ranged from to | 15 |
needed to be | 15 |
as long as | 15 |
hemolytic disease of | 15 |
growth factor receptor | 14 |
that they have | 14 |
at a large | 14 |
products for human | 14 |
in all patients | 14 |
throughout the world | 14 |
were used for | 14 |
a panel of | 14 |
for assessment of | 14 |
the likelihood of | 14 |
the status of | 14 |
for blood and | 14 |
imaging of the | 14 |
public health emergencies | 14 |
from whole blood | 14 |
the spread of | 14 |
significant impact on | 14 |
more than of | 14 |
that could be | 14 |
of the common | 14 |
is characterized by | 14 |
the fda approved | 14 |
safety evaluation of | 14 |
ensure that the | 14 |
that it is | 14 |
of the three | 14 |
is also a | 14 |
of novel coronavirus | 14 |
of children with | 14 |
at increased risk | 14 |
performed on the | 14 |
the conduct of | 14 |
of the asean | 14 |
in the table | 14 |
been used for | 14 |
in the plasma | 14 |
identification of the | 14 |
an opportunity to | 14 |
ease of use | 14 |
this type of | 14 |
be performed on | 14 |
test for the | 14 |
in the management | 14 |
for the future | 14 |
is difficult to | 14 |
o neg rbc | 14 |
of infectious diseases | 14 |
a better understanding | 14 |
of a variety | 14 |
infections associated with | 14 |
of antibiotic resistance | 14 |
acute myeloid leukemia | 14 |
of the development | 14 |
of the cases | 14 |
the time to | 14 |
yet to be | 14 |
period of time | 14 |
were treated with | 14 |
the utility of | 14 |
step in the | 14 |
effect on the | 14 |
were collected from | 14 |
was evaluated using | 14 |
are shown in | 14 |
the present study | 14 |
he will discuss | 14 |
adverse event reporting | 14 |
health care facilities | 14 |
current good manufacturing | 14 |
changes in the | 14 |
of pharmaceutical products | 14 |
described in the | 14 |
resulting in a | 14 |
creation of a | 14 |
of adverse events | 14 |
age of the | 14 |
the proportion of | 14 |
the control of | 14 |
and blood components | 14 |
of patients and | 14 |
solid organ transplant | 14 |
testing of the | 14 |
on the market | 14 |
university school of | 14 |
and the other | 14 |
of zika virus | 14 |
of the region | 14 |
access to the | 14 |
the clinical laboratory | 14 |
studies should be | 14 |
to measure the | 14 |
the alinity s | 14 |
the day of | 14 |
showed that the | 14 |
for the identification | 14 |
been used in | 14 |
vast majority of | 14 |
of the same | 14 |
patient information leaflet | 14 |
of the donors | 14 |
to make a | 14 |
not limited to | 14 |
the surface of | 14 |
in collaboration with | 14 |
play a role | 14 |
the manufacturing process | 14 |
to be able | 14 |
the first time | 14 |
blood stem cell | 14 |
is essential for | 14 |
were reported to | 14 |
high degree of | 14 |
appears to be | 14 |
the imaging findings | 14 |
defined as the | 14 |
a period of | 14 |
participate in the | 14 |
were compared to | 13 |
guidelines for the | 13 |
and specificity of | 13 |
a lot of | 13 |
in the european | 13 |
supplementary figure s | 13 |
findings of the | 13 |
may result in | 13 |
drug supply chain | 13 |
national and international | 13 |
of the ctd | 13 |
that the patient | 13 |
the transfusion medicine | 13 |
was evaluated on | 13 |
it can be | 13 |
hiv and hcv | 13 |
as a consequence | 13 |
study was performed | 13 |
in a recent | 13 |
was reported to | 13 |
a tertiary care | 13 |
a single market | 13 |
flexible gastrointestinal endoscopes | 13 |
technical requirements for | 13 |
which can be | 13 |
well as a | 13 |
was performed with | 13 |
all member states | 13 |
to allow for | 13 |
the immune response | 13 |
in spite of | 13 |
are present in | 13 |
seems to be | 13 |
of information and | 13 |
report of the | 13 |
of the gcc | 13 |
for the clinical | 13 |
in the fda | 13 |
moderate to severe | 13 |
is to review | 13 |
for more than | 13 |
expression of the | 13 |
for each of | 13 |
in an effort | 13 |
indicated that she | 13 |
blood bank and | 13 |
portion of the | 13 |
summary of the | 13 |
the relationship between | 13 |
such as a | 13 |
the administration of | 13 |
plays an important | 13 |
several studies have | 13 |
on the day | 13 |
results of the | 13 |
were subjected to | 13 |
of the endoscope | 13 |
be useful in | 13 |
the comparator assay | 13 |
was significantly higher | 13 |
ranging from to | 13 |
performed on a | 13 |
of a novel | 13 |
to play a | 13 |
for clinical use | 13 |
developed by the | 13 |
mild to moderate | 13 |
on day and | 13 |
of these lesions | 13 |
of information on | 13 |
objective was to | 13 |
patients who had | 13 |
of the products | 13 |
of this educational | 13 |
for which the | 13 |
of the us | 13 |
was approved by | 13 |
thought to be | 13 |
for medicinal products | 13 |
by the us | 13 |
the event of | 13 |
were performed in | 13 |
the fda for | 13 |
were detected in | 13 |
intended for use | 13 |
could lead to | 13 |
to enhance the | 13 |
in which a | 13 |
course of the | 13 |
well as in | 13 |
average number of | 13 |
but it is | 13 |
are the most | 13 |
was created in | 13 |
to have an | 13 |
ebola virus infection | 13 |
the patient is | 13 |
so that the | 13 |
specificity of the | 13 |
during the study | 13 |
with the fda | 13 |
the gold standard | 13 |
in the process | 13 |
bacterial contamination of | 13 |
the most frequent | 13 |
to prevent the | 13 |
with the exception | 13 |
clinically significant antibodies | 13 |
we performed a | 13 |
compared to other | 13 |
of the vector | 13 |
the beginning of | 13 |
shown in table | 13 |
efficacy of the | 13 |
likely due to | 13 |
that she will | 13 |
samples were collected | 13 |
the patient had | 13 |
rbcs stored for | 13 |
for the presence | 13 |
the clinical trial | 13 |
she will discuss | 13 |
us fda and | 13 |
when there is | 13 |
route of administration | 13 |
located in the | 13 |
is designed to | 13 |
be necessary to | 13 |
is important for | 13 |
phase i ii | 13 |
there are a | 13 |
be given to | 13 |
clinical trials are | 13 |
sterile drug products | 13 |
in these patients | 13 |
use of these | 13 |
performed in the | 13 |
and exchange of | 13 |
and there is | 13 |
it would be | 12 |
were identified in | 12 |
draft guidance for | 12 |
hemolytic transfusion reaction | 12 |
of viral load | 12 |
patients in the | 12 |
cooperation and harmonization | 12 |
a compounding pharmacy | 12 |
the early s | 12 |
as soon as | 12 |
more effective than | 12 |
not appear to | 12 |
will need to | 12 |
bone marrow transplantation | 12 |
to the patient | 12 |
lead to the | 12 |
the method of | 12 |
a critical role | 12 |
to test the | 12 |
detection of respiratory | 12 |
has been made | 12 |
for infectious disease | 12 |
the differential diagnosis | 12 |
for the rapid | 12 |
to confirm the | 12 |
day and day | 12 |
of our study | 12 |
in whole blood | 12 |
stem cell transplant | 12 |
for pediatric radiology | 12 |
seen in the | 12 |
gene therapy products | 12 |
with sickle cell | 12 |
the future of | 12 |
the exception of | 12 |
and assessment of | 12 |
in the vaccine | 12 |
and to the | 12 |
image gently campaign | 12 |
genotyping was performed | 12 |
to be tested | 12 |
high risk for | 12 |
the national dras | 12 |
the advent of | 12 |
limited number of | 12 |
of the phs | 12 |
as one of | 12 |
the drug was | 12 |
was found in | 12 |
with the same | 12 |
of these products | 12 |
even if the | 12 |
were performed with | 12 |
addition to these | 12 |
in patients receiving | 12 |
binds to the | 12 |
rna dependent rna | 12 |
clinical evaluation of | 12 |
results indicate that | 12 |
prior to transfusion | 12 |
data from the | 12 |
an analysis of | 12 |
and it was | 12 |
can be a | 12 |
emerging infectious diseases | 12 |
for hiv and | 12 |
order to ensure | 12 |
and clinical trials | 12 |
h n influenza | 12 |
use of blood | 12 |
were compared with | 12 |
the combination of | 12 |
by use of | 12 |
of technical requirements | 12 |
the pediatric patient | 12 |
in of cases | 12 |
have been described | 12 |
of the total | 12 |
overview of the | 12 |
to estimate the | 12 |
significantly higher in | 12 |
of the who | 12 |
direct antiglobulin test | 12 |
evaluation and research | 12 |
risk of transmission | 12 |
by the blood | 12 |
the cause of | 12 |
content and format | 12 |
results showed that | 12 |
available on the | 12 |
blood donor center | 12 |
is to provide | 12 |
to the use | 12 |
that would be | 12 |
in of the | 12 |
to illustrate the | 12 |
as it is | 12 |
european pharmaceutical system | 12 |
is involved in | 12 |
the transmission of | 12 |
and the united | 12 |
imaging findings in | 12 |
contribute to the | 12 |
global public health | 12 |
were positive for | 12 |
interpretation of the | 12 |
study was conducted | 12 |
cell lung cancer | 12 |
the interpretation of | 12 |
no evidence of | 12 |
or absence of | 12 |
of severe acute | 12 |
of the procedure | 12 |
not be used | 12 |
imaging features of | 12 |
as opposed to | 12 |
to be associated | 12 |
because it is | 12 |
may have a | 12 |
are required for | 12 |
college of medicine | 12 |
may be more | 12 |
in the public | 12 |
there may be | 12 |
we found that | 12 |
followed by a | 12 |
to the us | 12 |
in the assessment | 12 |
the care of | 12 |
systematic review of | 12 |
and quality of | 12 |
bmsc and amsc | 12 |
will not be | 12 |
between the us | 12 |
evaluation of pediatric | 12 |
of up to | 12 |
be noted that | 12 |
a pictorial review | 12 |
have been approved | 12 |
was isolated from | 12 |
the eu and | 12 |
are included in | 12 |
be performed in | 12 |
is important in | 12 |
results suggest that | 12 |
clinical trials and | 12 |
detected in the | 12 |
steering committee meeting | 12 |
the european parliament | 12 |
blood group system | 12 |
can be found | 12 |
the us food | 12 |
was no significant | 12 |
disease in the | 12 |
a high degree | 12 |
are summarized in | 12 |
harmonization of standards | 12 |
that did not | 12 |
the association between | 12 |
to minimize the | 12 |
may be useful | 12 |
united states and | 12 |
the occurrence of | 12 |
is expected to | 12 |
more than a | 12 |
the study of | 12 |
studies were performed | 12 |
summarized in table | 12 |
of these drugs | 12 |
margin of safety | 12 |
eu member states | 12 |
binding to the | 12 |
at a tertiary | 12 |
to monitor the | 12 |
the inhibition of | 12 |
to screen and | 12 |
were correlated with | 12 |
and compared to | 12 |
to occur in | 12 |
tests that are | 12 |
were reviewed for | 12 |
cleaning and disinfection | 12 |
countries in the | 12 |
be aware of | 12 |
can result in | 12 |
in food animals | 12 |
reported in of | 12 |
presence of the | 11 |
from january to | 11 |
they can be | 11 |
to establish a | 11 |
during the covid | 11 |
was less than | 11 |
is used for | 11 |
result of a | 11 |
can be identified | 11 |
performance of a | 11 |
in many cases | 11 |
of participants receiving | 11 |
be considered when | 11 |
indicate that the | 11 |
in the liver | 11 |
will be described | 11 |
for clinical trials | 11 |
college of radiology | 11 |
have been identified | 11 |
of the member | 11 |
the collection of | 11 |
used to identify | 11 |
to public health | 11 |
be considered in | 11 |
mouse model of | 11 |
the decision to | 11 |
under the animal | 11 |
is defined as | 11 |
recommended by the | 11 |
of the sadc | 11 |
a way to | 11 |
the european pharmaceutical | 11 |
epidermal growth factor | 11 |
the change in | 11 |
has been very | 11 |
but did not | 11 |
to years of | 11 |
a recent study | 11 |
statistically significant difference | 11 |
been developed to | 11 |
this can be | 11 |
important in the | 11 |
university medical center | 11 |
in the form | 11 |
are subject to | 11 |
bpa and bpn | 11 |
affected by the | 11 |
of the various | 11 |
were tested with | 11 |
were analyzed for | 11 |
have led to | 11 |
clinical and laboratory | 11 |
need for a | 11 |
duration of the | 11 |
be the most | 11 |
in the animal | 11 |
one patient had | 11 |
quality control of | 11 |
human genome project | 11 |
increases the risk | 11 |
of at least | 11 |
of human immunodeficiency | 11 |
and effectiveness of | 11 |
was the most | 11 |
the bact alert | 11 |
the samples were | 11 |
patients with scd | 11 |
not yet been | 11 |
member states and | 11 |
medicines in the | 11 |
to rbcs stored | 11 |
to see if | 11 |
should be performed | 11 |
vitamin d deficiency | 11 |
would be a | 11 |
to participate in | 11 |
are necessary to | 11 |
to patients with | 11 |
that resulted in | 11 |
by a single | 11 |
of blood transfusion | 11 |
was determined to | 11 |
as high as | 11 |
approved drugs against | 11 |
has been established | 11 |
component of the | 11 |
and maintenance of | 11 |
patient safety and | 11 |
the clinical trials | 11 |
the standard of | 11 |
activity of the | 11 |
the european community | 11 |
may have been | 11 |
a subset of | 11 |
is a relatively | 11 |
cov m pro | 11 |
presence or absence | 11 |
new automated alinity | 11 |
taking into account | 11 |
for the management | 11 |
the objectives of | 11 |
c and e | 11 |
in pag c | 11 |
administration of the | 11 |
referred to as | 11 |
of the other | 11 |
the limit of | 11 |
to be more | 11 |
most of these | 11 |
we were able | 11 |
drug discovery and | 11 |
due to their | 11 |
to treat covid | 11 |
test was used | 11 |
blood donors with | 11 |
use of an | 11 |
the association of | 11 |
resistant staphylococcus aureus | 11 |
the protection of | 11 |
from patients with | 11 |
significant increase in | 11 |
for use on | 11 |
the system and | 11 |
can be performed | 11 |
similar to the | 11 |
basis of the | 11 |
was identified in | 11 |
to examine the | 11 |
the eu has | 11 |
the disease and | 11 |
reported to occur | 11 |
information in the | 11 |
national institute of | 11 |
more than million | 11 |
removed from the | 11 |
serves as a | 11 |
is due to | 11 |
such as those | 11 |
is critical for | 11 |
performed to determine | 11 |
the distribution of | 11 |
of this exhibit | 11 |
also be discussed | 11 |
in the late | 11 |
there should be | 11 |
of a drug | 11 |
to the united | 11 |
of these studies | 11 |
of the literature | 11 |
focus on the | 11 |
there is little | 11 |
an important step | 11 |
fast brain mri | 11 |
it was agreed | 11 |
the clinical and | 11 |
time quantitative pcr | 11 |
was not statistically | 11 |
for the patient | 11 |
drugs and biologics | 11 |
the needs of | 11 |
version of the | 11 |
and distribution of | 11 |
the pediatric spine | 11 |
for diagnosis of | 11 |
known as the | 11 |
the fetus and | 11 |
immune response to | 11 |
review of all | 11 |
surface of the | 11 |
that will be | 11 |
the preparation of | 11 |
of the process | 11 |
on how to | 11 |
patients infected with | 11 |
critical in the | 11 |
with weak d | 11 |
the form of | 11 |
used as the | 11 |
goal was to | 11 |
information and patient | 11 |
by comparing the | 11 |
a case report | 11 |
risk of adverse | 11 |
allows for the | 11 |
between member states | 11 |
antibiotics in animal | 11 |
are not available | 11 |
of the samples | 11 |
are at risk | 11 |
two of the | 11 |
have to be | 11 |
donors with a | 11 |
the design of | 11 |
we reviewed the | 11 |
quality of medicines | 11 |
the analysis of | 11 |
public health service | 11 |
with the goal | 11 |
national institutes of | 11 |
response to a | 11 |
of hepatitis b | 11 |
against the virus | 11 |
endoscopic retrograde cholangiopancreatography | 11 |
rt on day | 11 |
which is the | 11 |
of all the | 11 |
focused on the | 11 |
taken into consideration | 11 |
effect of the | 11 |
to implement the | 11 |
an outbreak of | 11 |
automated alinity s | 11 |
critical role in | 11 |
was referred to | 11 |
harmonization and cooperation | 11 |
aim of the | 11 |
patients with chronic | 11 |
this exhibit is | 11 |
and the blood | 11 |
and has been | 11 |
the patients with | 11 |
on the development | 11 |
are known to | 11 |
mmol g hb | 11 |
were evaluated by | 11 |
issues related to | 11 |
of the best | 11 |
available in the | 11 |
implementation of ich | 10 |
characterization of the | 10 |
in the brain | 10 |
anatomy of the | 10 |
was not associated | 10 |
there are also | 10 |
a limited number | 10 |
hld or sterilization | 10 |
which there is | 10 |
may be due | 10 |
the onset of | 10 |
higher than the | 10 |
age and sex | 10 |
a pivotal role | 10 |
all patients with | 10 |
of medical products | 10 |
pictorial review of | 10 |
to the fact | 10 |
products in the | 10 |
and is used | 10 |
the first step | 10 |
regardless of the | 10 |
of the brain | 10 |
they should be | 10 |
for the production | 10 |
is required for | 10 |
in the patient | 10 |
sent to the | 10 |
from the national | 10 |
based on their | 10 |
for the following | 10 |
there are many | 10 |
parts of the | 10 |
of flight mass | 10 |
as much as | 10 |
antibodies in the | 10 |
in the near | 10 |
the content of | 10 |
of the harmonization | 10 |
trade and investment | 10 |
in the host | 10 |
society of gastroenterology | 10 |
bone marrow transplant | 10 |
good manufacturing practices | 10 |
approach to identify | 10 |
were reviewed by | 10 |
the type and | 10 |
has been applied | 10 |
have been a | 10 |
has been an | 10 |
were used as | 10 |
characteristics of the | 10 |
is also important | 10 |
there are several | 10 |
society for pediatric | 10 |
nucleic acid testing | 10 |
and blood products | 10 |
were more likely | 10 |
were transfused with | 10 |
and with the | 10 |
by reducing the | 10 |
broad spectrum of | 10 |
status of the | 10 |
during the development | 10 |
it is imperative | 10 |
for use by | 10 |
were prepared from | 10 |
nucleic acid amplification | 10 |
us and mri | 10 |
cov and sars | 10 |
to promote the | 10 |
the national level | 10 |
and the use | 10 |
the animal model | 10 |
small cell lung | 10 |
of the above | 10 |
be applied to | 10 |
needed to support | 10 |
in patient care | 10 |
blood donor screening | 10 |
is a human | 10 |
was shown to | 10 |
types of products | 10 |
used to compare | 10 |
to decrease the | 10 |
a timely manner | 10 |
data was collected | 10 |
of infectious disease | 10 |
the search for | 10 |
and after the | 10 |
contact with the | 10 |
will be able | 10 |
it is clear | 10 |
gold standard for | 10 |
and the development | 10 |
of american pathologists | 10 |
is possible that | 10 |
and the need | 10 |
the types of | 10 |
was obtained from | 10 |
are designed to | 10 |
tested on the | 10 |
form of the | 10 |
for the purpose | 10 |
neonatal intensive care | 10 |
the selection of | 10 |
in a clinical | 10 |
educational exhibit is | 10 |
determine the optimal | 10 |
for both the | 10 |
cd cells ml | 10 |
involvement of the | 10 |
on the surface | 10 |
the structure of | 10 |
id rhd xt | 10 |
the antibody screen | 10 |
is critical in | 10 |
of drug development | 10 |
platelet additive solution | 10 |
it was also | 10 |
then used to | 10 |
which can lead | 10 |
validation of the | 10 |
in the year | 10 |
will focus on | 10 |
the pharmaceutical sector | 10 |
from the blood | 10 |
it is worth | 10 |
not significantly different | 10 |
at that time | 10 |
in vitro studies | 10 |
a and c | 10 |
rapid detection of | 10 |
and hydrophobic interactions | 10 |
angiotensin receptor blockers | 10 |
top of the | 10 |
been developed for | 10 |
american association of | 10 |
method for the | 10 |
the in vitro | 10 |
a commercially available | 10 |
college of american | 10 |
our ability to | 10 |
health care providers | 10 |
a function of | 10 |
aid in the | 10 |
been linked to | 10 |
university of michigan | 10 |
c virus infection | 10 |
is a useful | 10 |
published in the | 10 |
of health care | 10 |
of the transfusion | 10 |
be taken into | 10 |
play an important | 10 |
weak d phenotype | 10 |
the initiation of | 10 |
different types of | 10 |
the h n | 10 |
norms and standards | 10 |
of respiratory viruses | 10 |
institutional review board | 10 |
were observed for | 10 |
at the blood | 10 |
hepatitis b surface | 10 |
the practice of | 10 |
occur in the | 10 |
certain types of | 10 |
compared to those | 10 |
be required to | 10 |
length of stay | 10 |
if the donor | 10 |
a prospective study | 10 |
sequencing of the | 10 |
no statistically significant | 10 |
in line with | 10 |
we sought to | 10 |
was sent to | 10 |
leading to a | 10 |
speci fi c | 10 |
the visionv r | 10 |
not have a | 10 |
and evaluation of | 10 |
will review the | 10 |
are intended to | 10 |
was no difference | 10 |
have been made | 10 |
on behalf of | 10 |
report a case | 10 |
can be easily | 10 |
the weak d | 10 |
are able to | 10 |
goal is to | 10 |
risk of infection | 10 |
it does not | 10 |
fda approved drug | 10 |
packed red blood | 10 |
blood donors were | 10 |
both of these | 10 |
to increase the | 10 |
medicine background case | 10 |
american society of | 10 |
of the following | 10 |
the scientific community | 10 |
cooperation in the | 10 |
their ability to | 10 |
sensitivity was evaluated | 10 |
the average number | 10 |
university of washington | 10 |
that the fda | 10 |
acute lung injury | 10 |
hbv and hcv | 10 |
is to demonstrate | 10 |
in recognition of | 10 |
respiratory tract infections | 10 |
the final product | 10 |
cobasv r zika | 10 |
and interpretation of | 10 |
different stages of | 10 |
no difference in | 10 |
phase iii trial | 10 |
results in a | 10 |
to achieve the | 10 |
effective use of | 10 |
the quality and | 10 |
the fda is | 10 |
if it is | 10 |
available for the | 10 |
an alternative to | 10 |
were stored at | 10 |
of gene therapy | 10 |
university of california | 10 |
is not always | 10 |
hydroxychloroquine and chloroquine | 10 |
were no significant | 10 |
key role in | 10 |
in children and | 10 |
the rhd gene | 10 |
use of medically | 10 |
the valid act | 10 |
of the genome | 10 |
linked to the | 10 |
because of its | 10 |
the host cell | 10 |
of the protein | 10 |
human papilloma virus | 10 |
components of the | 10 |
region of the | 10 |
our blood center | 10 |
monitoring of the | 10 |
the secretary of | 10 |
recognition of the | 10 |
with a new | 10 |
point of care | 10 |
introduced in the | 10 |
systematic review and | 10 |
to donate blood | 10 |
the goals of | 10 |
and so on | 10 |
red cross blood | 10 |
rapid diagnosis of | 10 |
we will review | 10 |
the time the | 10 |
the causative agent | 10 |
the choice of | 10 |
the benefit of | 10 |
of the population | 10 |
be found in | 10 |
this exhibit will | 10 |
adverse events were | 10 |
viral replication and | 10 |
for infectious diseases | 10 |
is supported by | 10 |
discovery and development | 10 |
patent ductus arteriosus | 10 |
for diagnostic tests | 10 |
in the present | 10 |
of biological products | 10 |
from the united | 10 |
as measured by | 10 |
and the risk | 10 |
prescribing information and | 10 |
and patient information | 10 |
of flexible endoscopes | 10 |
marrow donor program | 10 |
to understand the | 10 |
efficacy of a | 10 |
of the spr | 10 |
patients who have | 10 |
put in place | 10 |
units were transfused | 10 |
the differences in | 10 |
have access to | 10 |
recommendations for the | 10 |
that is used | 10 |
were performed by | 10 |
and are not | 10 |
would not be | 10 |
and sterilization of | 10 |
the fda issued | 10 |
group a plasma | 10 |
of the fd | 10 |
more difficult to | 10 |
contributed to the | 10 |
a statistically significant | 10 |
screen and identify | 10 |
to continue to | 10 |
and guidelines for | 10 |
and to determine | 10 |
and infectious diseases | 10 |
for a total | 10 |
studies are needed | 10 |
are available for | 10 |
of the high | 10 |
serologic weak d | 10 |
in this article | 10 |
were obtained with | 10 |
that they are | 10 |
of units of | 10 |
of ich guidelines | 10 |
majority of these | 10 |
director of the | 10 |
as a new | 10 |
blood donors and | 10 |
in more than | 10 |
the opportunity to | 9 |
and marrow transplantation | 9 |
information regarding the | 9 |
ml of plasma | 9 |
a concept paper | 9 |
does not appear | 9 |
antiviral activity of | 9 |
and review of | 9 |
samples obtained from | 9 |
tandem mass spectrometry | 9 |
they are used | 9 |
by binding to | 9 |
national marrow donor | 9 |
to the increased | 9 |
is clear that | 9 |
data can be | 9 |
will be a | 9 |
and the european | 9 |
an important tool | 9 |
this is particularly | 9 |
the late s | 9 |
and has a | 9 |
hematopoietic cell transplantation | 9 |
did not differ | 9 |
increased risk for | 9 |
pharmaceutical supply chain | 9 |
and the presence | 9 |
blood donors for | 9 |
the specificity of | 9 |
study conducted by | 9 |
under section b | 9 |
leading cause of | 9 |
to focus on | 9 |
and stored at | 9 |
been applied to | 9 |
of some of | 9 |
transferred to the | 9 |
study aimed to | 9 |
aim was to | 9 |
clinic background case | 9 |
as low as | 9 |
will have a | 9 |
it will be | 9 |
infectious disease testing | 9 |
is composed of | 9 |
symptoms such as | 9 |
blood system for | 9 |
the impact on | 9 |
performed using the | 9 |
particularly in the | 9 |
has been widely | 9 |
in the manufacturing | 9 |
but also the | 9 |
immunoassay for the | 9 |
a high level | 9 |
university of pennsylvania | 9 |
this is especially | 9 |
of the risk | 9 |
the range of | 9 |
a safe and | 9 |
mode of action | 9 |
protection of public | 9 |
time of the | 9 |
a significant decrease | 9 |
findings of a | 9 |
the demand for | 9 |
depend on the | 9 |
and that the | 9 |
public and private | 9 |
associated with an | 9 |
standard operating procedures | 9 |
age and weight | 9 |
have demonstrated that | 9 |
to protect against | 9 |
that should be | 9 |
are used for | 9 |
were assessed for | 9 |
identity of the | 9 |
the replication of | 9 |
delayed hemolytic transfusion | 9 |
blood donors in | 9 |
a key role | 9 |
concern about the | 9 |
were selected for | 9 |
review was performed | 9 |
of the drugs | 9 |
of the laboratory | 9 |
and reduce the | 9 |
of respiratory syncytial | 9 |
has been suggested | 9 |
organ transplant recipients | 9 |
to analyze the | 9 |
for whole blood | 9 |
antibody screen and | 9 |
appropriate use of | 9 |
to the extent | 9 |
data suggest that | 9 |
in the use | 9 |
ortho clinical diagnostics | 9 |
these results suggest | 9 |
among blood donors | 9 |
on the safety | 9 |
human clinical trials | 9 |
the most effective | 9 |
a need to | 9 |
who have been | 9 |
autoimmune hemolytic anemia | 9 |
the mean number | 9 |
is limited to | 9 |
management of the | 9 |
they are not | 9 |
accordance with the | 9 |
been made in | 9 |
to aid in | 9 |
on the type | 9 |
took place in | 9 |
approval of the | 9 |
of less than | 9 |
cytokine release syndrome | 9 |
less than of | 9 |
a retrospective analysis | 9 |
indicated that the | 9 |
was evaluated for | 9 |
studies have been | 9 |
pc in plasma | 9 |
the detection and | 9 |
of a patient | 9 |
the problem of | 9 |
number of donors | 9 |
the pharmacokinetics of | 9 |
safety of blood | 9 |
a small number | 9 |
entry into the | 9 |
rather than a | 9 |
derived from the | 9 |
are expected to | 9 |
high level of | 9 |
is safe and | 9 |
was added to | 9 |
to optimize the | 9 |
ct radiation dose | 9 |
to be considered | 9 |
medically important antibiotics | 9 |
false positive results | 9 |
absence of a | 9 |
the generation of | 9 |
children and adolescents | 9 |
prenatal and postnatal | 9 |
a framework for | 9 |
in place to | 9 |
resulted in an | 9 |
acute respiratory distress | 9 |
the registration of | 9 |
are essential for | 9 |
completion of the | 9 |
rbc units were | 9 |
a retrospective study | 9 |
for this reason | 9 |
as a treatment | 9 |
total of patients | 9 |
of viral infections | 9 |
the influence of | 9 |
for prevention of | 9 |
samples were taken | 9 |
performed a retrospective | 9 |
blood loss and | 9 |
the concept paper | 9 |
we hypothesized that | 9 |
of the original | 9 |
the potential of | 9 |
the office of | 9 |
suggesting that the | 9 |
the society for | 9 |
into account the | 9 |
relationship between the | 9 |
into the host | 9 |
to the drug | 9 |
adverse drug reactions | 9 |
was assessed by | 9 |
on the same | 9 |
and more than | 9 |
the council of | 9 |
the immucor neo | 9 |
for the majority | 9 |
position of the | 9 |
of hepatitis c | 9 |
referred to the | 9 |
progress has been | 9 |
the center for | 9 |
the biological product | 9 |
level of the | 9 |
in developing countries | 9 |
of the normal | 9 |
the vaccine industry | 9 |
at c for | 9 |
entered into force | 9 |
use in animal | 9 |
in individuals with | 9 |
of nucleic acid | 9 |
effects of the | 9 |
of standards and | 9 |
and detection of | 9 |
and administration of | 9 |
a mean of | 9 |
a pediatric patient | 9 |
adopted by the | 9 |
the college of | 9 |
of congenital heart | 9 |
is a need | 9 |
for molecular pathology | 9 |
were similar to | 9 |
a high titer | 9 |
patients who underwent | 9 |
with the highest | 9 |
access to testing | 9 |
a single unit | 9 |
to provide the | 9 |
and risk of | 9 |
for each patient | 9 |
desorption ionization time | 9 |
the costs of | 9 |
crystal structure of | 9 |
and biological products | 9 |
was performed and | 9 |
over the next | 9 |
severity of the | 9 |
all aspects of | 9 |
aim is to | 9 |
may be required | 9 |
ct and mr | 9 |
study published in | 9 |
scope of the | 9 |
have developed a | 9 |
we have developed | 9 |
is in the | 9 |
in critically ill | 9 |
if there is | 9 |
risk factor for | 9 |
by using the | 9 |
a and anti | 9 |
antiviral drugs were | 9 |
report of a | 9 |
in the pre | 9 |
mean number of | 9 |
that may not | 9 |
suggests that the | 9 |
have been established | 9 |
response to therapy | 9 |
for transmission of | 9 |
studies have demonstrated | 9 |
spread of the | 9 |
which resulted in | 9 |
the length of | 9 |
can be observed | 9 |
in the health | 9 |
order to be | 9 |
mri of the | 9 |
the patient population | 9 |
in the medical | 9 |
white blood cell | 9 |
positive and negative | 9 |
patient with a | 9 |
hcv and hiv | 9 |
of the group | 9 |
hospital transfusion service | 9 |
the coordination of | 9 |
for red blood | 9 |
and the number | 9 |
limited by the | 9 |
by standard tube | 9 |
is used as | 9 |
for the registration | 9 |
in the viral | 9 |
by the national | 9 |
nucleic acid test | 9 |
although there is | 9 |
produced by streptomyces | 9 |
the pharmaceutical domain | 9 |
high titer anti | 9 |
at a dose | 9 |
has not yet | 9 |
of the university | 9 |
in the current | 9 |
of these donors | 9 |
of the four | 9 |
recommendations from the | 9 |
the efficiency of | 9 |
is likely to | 9 |
differences between the | 9 |
in a small | 9 |
activities of the | 9 |
large numbers of | 9 |
von willebrand factor | 9 |
is essential in | 9 |
the united nations | 9 |
septic transfusion reactions | 9 |
at a rate | 9 |
procedures for the | 9 |
the host cells | 9 |
of the rhd | 9 |
for the same | 9 |
role of the | 9 |
in one study | 9 |
respiratory distress syndrome | 9 |
did not meet | 9 |
potential inhibitors of | 9 |
the emergency blood | 9 |
was collected from | 9 |
risk of transfusion | 9 |
a pictorial essay | 9 |
to implement a | 9 |
donor screening and | 9 |
in areas of | 9 |
by inhibiting the | 9 |
were analyzed using | 9 |
statistical analysis was | 9 |
to the same | 9 |
of coronavirus disease | 9 |
to identify and | 9 |
and marrow transplant | 9 |
patients with the | 9 |
for a large | 9 |
drug repurposing approach | 9 |
of the distal | 9 |
was performed at | 9 |
in one patient | 9 |
months to years | 9 |
the list of | 9 |
and at least | 9 |
is that the | 9 |
the central nervous | 9 |
the release of | 9 |
is related to | 9 |
various types of | 9 |
regional office for | 9 |
old female with | 9 |
in light of | 9 |
present a case | 9 |
be considered as | 9 |
was measured using | 9 |
were performed using | 9 |
along with a | 9 |
of the central | 9 |
since its creation | 9 |
in the identification | 9 |
imaging findings and | 9 |
the control group | 9 |
could result in | 9 |
of this article | 9 |
review and meta | 9 |
can be achieved | 9 |
hb deferral rates | 9 |
each member state | 9 |
benign and malignant | 9 |
performed by the | 9 |
may be associated | 9 |
for the most | 9 |
result of the | 9 |
technical and scientific | 9 |
of the covid | 9 |
has become a | 9 |
to be in | 9 |
us and eu | 9 |
the national institutes | 9 |
at a single | 9 |
than of the | 9 |
x l and | 9 |
a significant difference | 9 |
and did not | 9 |
compared to controls | 9 |
is recommended for | 9 |
have been associated | 9 |
detection of the | 9 |
and also the | 9 |
image quality and | 9 |
the challenges of | 9 |
the novel coronavirus | 9 |
function of the | 9 |
required for the | 9 |
data needed to | 9 |
of the two | 9 |
b surface antigen | 9 |
is to determine | 9 |
that the product | 9 |
critical for the | 9 |
it was found | 9 |
on the status | 9 |
approximately of patients | 9 |
hospital medical center | 9 |
were analyzed by | 9 |
be helpful in | 9 |
an example of | 9 |
a significant role | 9 |
of the relevant | 9 |
from donors with | 9 |
the spinal cord | 9 |
performed in a | 9 |
rhd and rhce | 9 |
to respond to | 9 |
we report the | 9 |
of the different | 9 |
and approval of | 9 |
sensitivity of the | 9 |
relation to the | 9 |
and duration of | 9 |
the appearance of | 9 |
soft tissue masses | 9 |
significantly lower in | 9 |
these studies are | 9 |
in solid organ | 8 |
to create an | 8 |
would like to | 8 |
to the right | 8 |
in vitro diagnostic | 8 |
dependent on the | 8 |
of blood product | 8 |
in the previous | 8 |
retrospective study of | 8 |
phase ii clinical | 8 |
antibody screen was | 8 |
community hospitals and | 8 |
molecule antiviral drugs | 8 |
stages of development | 8 |
isolated from wbcs | 8 |
center for drug | 8 |
of this initiative | 8 |
was conducted to | 8 |
our blood bank | 8 |
during the time | 8 |
results were compared | 8 |
event reporting system | 8 |
it was noted | 8 |
health and disease | 8 |
similar to those | 8 |
for apheresis platelets | 8 |
lung disease in | 8 |
of antibiotic use | 8 |
drugs such as | 8 |
the safety profile | 8 |
the site of | 8 |
fda approval for | 8 |
what has been | 8 |
to the ema | 8 |
in the laboratory | 8 |
an increased risk | 8 |
on the ich | 8 |
arterial tortuosity syndrome | 8 |
to complete the | 8 |
and is a | 8 |
and there are | 8 |
a month period | 8 |
of medical countermeasures | 8 |
amplicor mycobacterium tuberculosis | 8 |
b of the | 8 |
of safety and | 8 |
routes of administration | 8 |
human challenge studies | 8 |
can only be | 8 |
drug products from | 8 |
published by the | 8 |
may be at | 8 |
blood components were | 8 |
for which there | 8 |
hospital for sick | 8 |
representatives from the | 8 |
for some of | 8 |
drug administration fda | 8 |
free movement of | 8 |
case of the | 8 |
results of these | 8 |
c difficile spores | 8 |
in animals and | 8 |
this retrospective study | 8 |
wide spectrum of | 8 |
the two groups | 8 |
for many years | 8 |
of the tumor | 8 |
none of these | 8 |
a risk of | 8 |
have resulted in | 8 |
served as a | 8 |
to allow the | 8 |
results were obtained | 8 |
as described in | 8 |
of the recipient | 8 |
of vascular anomalies | 8 |
meeting of the | 8 |
increasing number of | 8 |
more than times | 8 |
a collection of | 8 |
was developed to | 8 |
transfusion of blood | 8 |
to the number | 8 |
of each of | 8 |
may contribute to | 8 |
replication and transcription | 8 |
has been demonstrated | 8 |
the sensitivity and | 8 |
reducing the risk | 8 |
review of a | 8 |
harmonization of the | 8 |
is consistent with | 8 |
of the association | 8 |
human and animal | 8 |
reagent red cells | 8 |
regulatory authorities and | 8 |
fda and ema | 8 |
order to provide | 8 |
of the great | 8 |
of this presentation | 8 |
to limit the | 8 |
national cancer institute | 8 |
and characterization of | 8 |
to achieve this | 8 |
in this chapter | 8 |
of the agent | 8 |
for viral replication | 8 |
an attempt to | 8 |
and computed tomography | 8 |
hospital of philadelphia | 8 |
that there are | 8 |
in many countries | 8 |
isrs were reported | 8 |
the fda also | 8 |
the survey was | 8 |
this may be | 8 |
entered into the | 8 |
and those with | 8 |
the healthcare system | 8 |
the table below | 8 |
the approval process | 8 |
decreased from to | 8 |
been able to | 8 |
depends on the | 8 |
of the program | 8 |